Jacobsen Biotech ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 0.0% 20.2% 14.2%  
Credit score (0-100)  0 0 0 5 14  
Credit rating  N/A N/A N/A B BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Net sales  0 0 0 235 4  
Gross profit  0.0 0.0 0.0 232 -14.6  
EBITDA  0.0 0.0 0.0 84.1 -14.6  
EBIT  0.0 0.0 0.0 84.1 -14.6  
Pre-tax profit (PTP)  0.0 0.0 0.0 81.6 -17.6  
Net earnings  0.0 0.0 0.0 -0.1 -17.6  
Pre-tax profit without non-rec. items  0.0 0.0 0.0 81.6 -17.6  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 0.0 40.1 24.9  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 0.0 0.0 42.4 24.9  

Net Debt  0.0 0.0 0.0 -42.4 -14.9  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12

Net sales  0 0 0 235 4  
Net sales growth  0.0% 0.0% 0.0% 0.0% -98.3%  
Gross profit  0.0 0.0 0.0 232 -14.6  
Gross profit growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 -147.7 0.0  
Balance sheet total (assets)  0 0 0 42 25  
Balance sheet change%  0.0% 0.0% 0.0% 0.0% -41.4%  
Added value  0.0 0.0 0.0 231.8 -14.6  
Added value %  0.0% 0.0% 0.0% 98.6% -364.2%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 -1.0  
EBIT trend  0.0 0.0 0.0 1.0 -1.0  

Profitability 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 35.8% -364.2%  
EBIT %  0.0% 0.0% 0.0% 35.8% -364.2%  
EBIT to gross profit (%)  0.0% 0.0% 0.0% 36.3% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% -0.1% -438.9%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% -0.1% -438.9%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 34.7% -438.9%  
ROA %  0.0% 0.0% 0.0% 198.3% -43.3%  
ROI %  0.0% 0.0% 0.0% 209.5% -44.8%  
ROE %  0.0% 0.0% 0.0% -0.4% -54.0%  

Solidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 0.0% 94.6% 100.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 1.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% -17.1% -371.6%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.0% -50.4% 102.0%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.0 18.6 0.0  
Current Ratio  0.0 0.0 0.0 18.6 0.0  
Cash and cash equivalent  0.0 0.0 0.0 42.4 14.9  

Capital use efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 18.1% 371.6%  
Net working capital  0.0 0.0 0.0 40.1 14.9  
Net working capital %  0.0% 0.0% 0.0% 17.1% 371.6%  

Employee efficiency 
2019
N/A
2020
N/A
2021
N/A
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0